Jamison Grailer

Senior Research Scientist
Promega Corporation

​

Jamison Grailer is a Senior Research Scientist at Promega Corporation, where he leads the Biologics R&D Team. His lab is focused on leveraging Promega’s cutting-edge technology to create innovative bioanalytical tools that drive the discovery and development of biological therapeutics. Dr. Grailer has over a decade of experience in assay development and has authored more than 50 peer-reviewed publications, book chapters, and patents. Prior to joining Promega, he completed postdoctoral training in innate immunity at the University of Michigan Medical School.
​

 

Speech title & Synopsis

Talk 1: The Bioluminescent Toolbox for Vaccine Characterization and mRNA Quality Control
 
Talk 2: Bioluminescent Platform Technologies for Functional Characterization of Advanced Cancer Therapeutics
 

Talk 1: The Bioluminescent Toolbox for Vaccine Characterization and mRNA Quality Control
We present a suite of luminescent bioassays that enable rapid, quantitative assessment of vaccine-induced antibody responses and mRNA vaccine quality. To measure functional humoral immunity, we apply cell-based reporter bioassays for antibody-dependent cellular cytotoxicity (ADCC) and virus neutralization. The ADCC assay uses FcγRIII-expressing reporter cells to quantify effector activation, while the neutralization assay employs HiBiT-tagged pseudovirus-like particles (HiBiT-PsVLPs) and LgBiT-expressing target cells, generating a luminescent signal that is inhibited by virus neutralizing antibodies. Both platforms are adaptable to detect responses against multiple viral families. For mRNA vaccine quality, we introduce a novel luminescent assay for double-stranded RNA (dsRNA) contaminants using NanoBiT®-fused dsRNA-binding domains, offering high sensitivity (LoD < 1pg/ml) and specificity in a no-wash, mix-and-read format. A cell-based assay for dsRNA detection will also be presented. Together, these tools support innovation in mRNA vaccine research and production, providing high throughput, biosafe platform solutions for characterizing immune responses and ensuring therapeutic mRNA quality.
 
 
Talk 2: Bioluminescent Platform Technologies for Functional Characterization of Advanced Cancer Therapeutics
Innovative bioassay platform technologies were designed to accelerate the discovery, characterization, and release testing of next-generation cell therapies and antibody-drug conjugates (ADCs). The HiBiT-based Target Cell Killing (TCK) platform quantifies cytolysis in response to CAR-T, TCR-T, or antibody-mediated effector functions using NanoBiT® detection. Viascript™ TCK expands this capability to virtually any target cell type. Complementary Lumit® Immunoassays offer rapid, mix-and-read cytokine detection with high sensitivity and throughput. A novel lentivirus titering assay using a cell-based reporter bioassay streamlines CAR vector qualification. In support of ADC development, luminescent assays enable measurement of antigen binding and killing, including bystander effects. Collectively, these MoA-reflective, homogeneous assays provide robust, quantitative data that support preclinical screening, process development, and potency testing across a wide range of immunotherapy modalities.